RIGEL PHARMACEUTICALS, INC. Operating Cash Flow
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Operating Cash Flow of $33.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $30.65M, a 0.38% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $2.73M.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $21.98M, a 51.55% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $24.03M, a 10.85% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was $75.66M, a 140.40% increase from fiscal 2024.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was $31.47M.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$5.74M.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$73.76M, a 1354.81% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $33.38M 10-Q · filed 2026-08-04 | $55.36M derived: sum of 3 quarters · filed 2026-08-04 | $79.39M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.73M 10-Q · filed 2026-05-05 | $24.70M derived: sum of 2 quarters · filed 2026-05-05 | $48.74M derived: sum of 3 quarters · filed 2026-05-05 | $79.27M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $21.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $46.01M derived: sum of 2 quarters · filed 2026-03-03 | $76.55M derived: sum of 3 quarters · filed 2026-08-04 | $75.66M 10-K · filed 2026-03-03 |
| 2025-09-30 | $24.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $54.57M derived: sum of 2 quarters · filed 2026-08-04 | $53.67M 10-Q · filed 2025-11-04 | $68.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $30.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $29.64M 10-Q · filed 2026-08-04 | $44.15M derived: sum of 3 quarters · filed 2026-08-04 | $65.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$893.00K 10-Q · filed 2026-05-05 | $13.61M derived: sum of 2 quarters · filed 2026-05-05 | $35.29M derived: sum of 3 quarters · filed 2026-05-05 | $35.59M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $14.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $36.18M derived: sum of 2 quarters · filed 2026-03-03 | $36.48M derived: sum of 3 quarters · filed 2026-03-03 | $31.47M 10-K · filed 2026-03-03 |
| 2024-09-30 | $21.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $21.98M derived: sum of 2 quarters · filed 2025-11-04 | $16.97M 10-Q · filed 2025-11-04 | $10.73M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $302.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$4.71M 10-Q · filed 2025-08-05 | -$10.95M derived: sum of 3 quarters · filed 2026-03-03 | -$12.31M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$5.01M 10-Q · filed 2025-05-06 | -$11.25M derived: sum of 2 quarters · filed 2026-03-03 | -$12.61M derived: sum of 3 quarters · filed 2026-03-03 | -$6.68M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$6.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$7.60M derived: sum of 2 quarters · filed 2026-03-03 | -$1.67M derived: sum of 3 quarters · filed 2026-03-03 | -$5.74M 10-K · filed 2026-03-03 |
| 2023-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.57M derived: sum of 2 quarters · filed 2024-11-07 | $497.00K 10-Q · filed 2024-11-07 | -$21.41M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $5.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.86M 10-Q · filed 2024-08-06 | -$20.05M derived: sum of 3 quarters · filed 2025-03-04 | -$33.35M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | -$4.07M 10-Q · filed 2024-05-07 | -$25.98M derived: sum of 2 quarters · filed 2025-03-04 | -$39.28M derived: sum of 3 quarters · filed 2025-03-04 | -$52.20M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | -$21.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$35.21M derived: sum of 2 quarters · filed 2025-03-04 | -$48.12M derived: sum of 3 quarters · filed 2025-03-04 | -$73.76M 10-K · filed 2025-03-04 |
| 2022-09-30 | -$13.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$26.21M derived: sum of 2 quarters · filed 2023-11-07 | -$51.85M 10-Q · filed 2023-11-07 | -$70.94M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | -$12.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$38.55M 10-Q · filed 2023-08-01 | -$57.63M derived: sum of 3 quarters · filed 2024-03-05 | -$67.93M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | -$25.64M 10-Q · filed 2023-05-02 | -$44.72M derived: sum of 2 quarters · filed 2024-03-05 | -$55.02M derived: sum of 3 quarters · filed 2024-03-05 | $196.00K derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | -$19.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$29.38M derived: sum of 2 quarters · filed 2024-03-05 | $25.83M derived: sum of 3 quarters · filed 2024-03-05 | $5.88M 10-K · filed 2024-03-05 |
| 2021-09-30 | -$10.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $44.92M derived: sum of 2 quarters · filed 2022-11-03 | $24.96M 10-Q · filed 2022-11-03 | $9.39M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $55.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $35.26M 10-Q · filed 2022-08-02 | $19.69M derived: sum of 3 quarters · filed 2023-03-07 | $207.00K derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | -$19.95M 10-Q · filed 2022-05-03 | -$35.53M derived: sum of 2 quarters · filed 2023-03-07 | -$55.01M derived: sum of 3 quarters · filed 2023-03-07 | -$69.05M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | -$15.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$35.05M derived: sum of 2 quarters · filed 2023-03-07 | -$49.09M derived: sum of 3 quarters · filed 2023-03-07 | -$52.19M 10-K · filed 2023-03-07 |
| 2020-09-30 | -$19.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$33.52M derived: sum of 2 quarters · filed 2021-11-02 | -$36.61M 10-Q · filed 2021-11-02 | -$46.26M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$14.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$17.13M 10-Q · filed 2021-08-03 | -$26.78M derived: sum of 3 quarters · filed 2022-03-01 | -$41.42M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$3.09M 10-Q · filed 2021-05-05 | -$12.74M derived: sum of 2 quarters · filed 2022-03-01 | -$27.38M derived: sum of 3 quarters · filed 2022-03-01 | -$44.03M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$9.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$24.29M derived: sum of 2 quarters · filed 2022-03-01 | -$40.94M derived: sum of 3 quarters · filed 2022-03-01 | -$41.51M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$14.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$31.29M derived: sum of 2 quarters · filed 2020-11-05 | -$31.86M 10-Q · filed 2020-11-05 | -$20.22M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-06-30 | -$16.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$17.22M 10-Q · filed 2020-08-04 | -$5.58M derived: sum of 3 quarters · filed 2021-03-02 | -$25.66M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-03-31 | -$569.00K 10-Q · filed 2020-05-05 | $11.07M derived: sum of 2 quarters · filed 2021-03-02 | -$9.01M derived: sum of 3 quarters · filed 2021-03-02 | -$36.00M derived: sum of 4 quarters · filed 2021-03-02 |
| 2018-12-31 | $11.64M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | -$8.44M derived: sum of 2 quarters · filed 2021-03-02 | -$35.43M derived: sum of 3 quarters · filed 2021-03-02 | -$58.83M 10-K · filed 2021-03-02 |
| 2018-09-30 | -$20.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$47.08M derived: sum of 2 quarters · filed 2019-11-05 | -$70.47M 10-Q · filed 2019-11-05 | -$90.19M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$26.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$50.39M 10-Q · filed 2019-08-06 | -$70.10M derived: sum of 3 quarters · filed 2020-02-27 | -$87.71M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$23.39M 10-Q · filed 2019-05-07 | -$43.11M derived: sum of 2 quarters · filed 2020-02-27 | -$60.72M derived: sum of 3 quarters · filed 2020-02-27 | -$80.19M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$19.71M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$37.33M derived: sum of 2 quarters · filed 2020-02-27 | -$56.80M derived: sum of 3 quarters · filed 2020-02-27 | -$77.56M 10-K · filed 2020-02-27 |
| 2017-09-30 | -$17.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$37.08M derived: sum of 2 quarters · filed 2018-11-06 | -$57.84M 10-Q · filed 2018-11-06 | -$70.31M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | -$19.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$40.23M 10-Q · filed 2018-08-08 | -$52.70M derived: sum of 3 quarters · filed 2019-02-28 | -$75.27M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | -$20.76M 10-Q · filed 2018-05-01 | -$33.23M derived: sum of 2 quarters · filed 2019-02-28 | -$55.80M derived: sum of 3 quarters · filed 2019-02-28 | |
| 2016-12-31 | -$12.46M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$35.03M derived: sum of 2 quarters · filed 2019-02-28 | -$75.89M 10-K · filed 2019-02-28 | |
| 2016-09-30 | -$22.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$63.42M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | -$40.85M 10-Q · filed 2017-08-01 | |||
| 2015-12-31 | -$23.41M 10-K · filed 2018-03-06 | |||
| 2011-06-30 | -$37.93M 10-Q · filed 2011-08-02 | |||
| 2010-06-30 | $55.48M 10-Q · filed 2011-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |